



Internal Audit Plan: COVID-19 Impact (2nd Revision)

Swansea Bay University Health Board

NHS Wales Shared Services Partnership Audit & Assurance Services



1. INTRODUCTION

This paper is seeking the approval of the Audit Committee for changes proposed to the Internal Audit plan for 2020/21.

2. BACKGROUND

The Internal Audit Plan 2020/21 was originally agreed at the Audit Committee in March 2020. In view of the impact of Covid-19 on the management of services and risk profile of NHS organisations in Wales, internal audit work was suspended during the first Quarter of 2020/21. Before resuming work the audit plan was reviewed and initial, proposed revisions were presented to the Executive Board in June and approved by the Audit Committee in July.

While the first pandemic peak has subsided, the impact of Covid-19 is still being felt within the health board as services are reset. Management indicate continued staffing pressures arising from absences due to the infection and the associated isolation arrangements for those exposed to it. It is recognised that in this context some management initiatives have been delayed, and in respect of previous internal audit recommendations, the timescales for addressing some of the actions agreed have been protracted. The audit plan remains flexible and it is appropriate that we keep its content and timelines under review.

A number of audits were re-scheduled or deferred for future-year coverage following our first review in July. We have identified further audits for which reconsideration of timing and/or approach is appropriate. Proposals have been shared with Executive Directors and in line with feedback received, the Plan has been marked with proposed changes and is attached for Audit Committee consideration and approval.

3. RECOMMENDATION

The Audit Committee is asked to approve the changes marked within the second revision of the Internal Audit Plan 2020/21 at Appendix A.

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)					
Corporate governance, risk and regulatory compliance										
Annual Governance Statement (AGS)	001		To provide commentary on key aspects of Board governance to underpin the completion of the statement.	Director of Corporate Governance	Q4/5					
Governance, Leadership & Accountability (Health & Care Standards)	002		To provide a commentary on the process and evidence used to support the Health Board's selfassessment against the Healthcare Standards.	Director of Nursing & Patient Experience cc Director of Corporate Governance	Q4/5					
Risk Management & Board Assurance Framework (BAF)	003		To review the overall board assurance framework and risk management arrangements	Director of Corporate Governance	Q3					
			The scope of this audit will be limited to a follow up of the previous audit recommendations and consideration of progress against issues raised in the Covid Governance review.							
Health & Safety Framework (Follow Up)	004	64	To review action taken to improve the health & safety governance framework following the 2019/20 internal audit review.	Director of Nursing & Patient Experience cc Director of Corporate Governance, Chief Operating Officer	Q3					

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Controlled Drugs Governance Framework	005	57	To review the implementation of the Health Board's Controlled Drug Governance Framework and the assurance it provides in respect of legislative compliance.	Clinical Director of Pharmacy & Medicines Management cc Chief Operating Officer, Executive Medical Director, Director of Corporate Governance	Q3
HTA Compliance: Mortuary (Follow Up)	006		To review action taken to improve arrangements following the 2019/20 internal audit review.	Chief Operating Officer	Q2 FINAL REPORT
Hosted Body: Operational Delivery Network (Major Trauma)	007		To review operation of the governance arrangements agreed for this hosted body.	Director of Corporate Governance	Q4 → late Q3

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
COVID-19 Governance Review (All Wales additional review)	044		The aim of this advisory review is to assess the adequacy and effectiveness of internal controls in operation during the Covid-19 outbreak, with particular regard to the Principles and guidance set out by the Welsh Government. Any weaknesses will then be brought to the attention of management and advice issued on how particular problems may be resolved and control improved to minimise future occurrence.	Director of Corporate Governance / Director of Finance	Q2 FINAL REPORT
COVID-19 Decision Records *NEW*	045		The audit will review action taken to improve record-keeping arrangements following the advisory COVID-19 Governance Review. Detailed scope to be agreed with Executive leads.	Director of Finance / Director of Corporate Governance	Proposed addition to Audit Plan Q4
Corporate governance, risk and regulatory compliance domain subtotal	8→9 Audits				

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)			
Strategic planning performance management and reporting								
IMTP Development: Quality Impact Assessment (Follow Up)	008		To review action taken to improve arrangements following the 2019/20 internal audit review.	Director of Nursing & Patient Experience	Q2 → Remove from Plan (Include principle of Quality Impact Assessment in Planned Care audit)			
Primary Care Cluster Plans & Delivery	013	60	To review primary care cluster plans and arrangements in place to monitor their delivery.	Chief Operating Officer	Q2 In Progress			
Vaccinations & Immunisations (Follow Up)	014	15	To review action taken to improve arrangements following the 2018/19 internal audit review.	Director of Public Health cc Chief Operating Officer	Q2 DRAFT REPORT			
Planned Care (Essential Services)	015	16	To review arrangements in place to manage the re-setting of essential services. The scope of this audit will consider quality impact assessment.	Director of Finance / Associate Director of Performance & Finance cc Chief Operating Officer	Q2 TBC → Q3			
Strategic planning performance management and reporting domain subtotal	4→3 Audits							

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)				
Financial Governance and management									
Financial Plan: Delivery Framework	016	42	To review arrangements in place to deliver financial plans, including action taken following the 2019/20 KPMG review.	Director of Finance cc Chief Operating Officer	Q3 → Q4				
Procurement & Tendering: No Purchase Order, No Pay (Follow Up)	017		To review action taken to improve arrangements following the 2019/20 internal audit review.	Director of Finance cc Chief Operating Officer	Late Q2 → Defer to 2021/22				
Charitable Funds	018		To review the governance framework operating to ensure the effective management of Health Board charitable funds. Scope to be agreed, but may include consideration of previous coverage of the Golau fund and/or more recent Covid processes (subject to considerations within the separate COVID-19 Governance Review).	Director of Finance	Q2 Fieldwork closing				
Welsh Risk Pool Reimbursement Claims	019		To review documentation supporting WRP reimbursement claims, in accordance with WRP requirements.	Director of Finance	Q3 FINAL REPORT				

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Financial Governance and management domain sub-total	4→3 Audits				
Clinical governance qualit	y & safet	У			
Annual Quality Statement	020		The Board must assure itself that information published in the AQS is both accurate and representative. To support this, we will review the consistency of key information within the Draft AQS against information previously reported in the public domain and provide commentary to management.	Director of Nursing & Patient Experience	Q2 FINAL REPORT
Quality & Safety Governance Framework	021		To review the framework implemented to monitor & manage the quality & safety of services and provide assurance to the Board. The audit will consider action taken in response to any recommendations arising from the 2019/20 WAO Quality Governance review.	Director of Nursing & Patient Experience cc Chief Operating Officer, Executive Medical Director	Q3 → Defer to 2021/22
Ward Quality Assurance Framework	023		To review the implementation of the ward-to-board quality assurance framework (and	Director of Nursing & Patient Experience cc Chief Operating	Q2 → Defer to 2021/22

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
			changes made following the 2018/19 internal audit review).	Officer, Executive Medical Director	
Concerns & Redress	024		To review corporate arrangements in place to ensure incidents and complaints are managed in accordance with Welsh Government requirements and Health Board policies and procedures.	Director of Corporate Governance cc Director of Nursing & Patient Experience	Q3 → Q4
Infection Control	025	4	To review arrangements in place to manage the risk in infection, with a focus on cleaning.	Director of Nursing & Patient Experience cc Executive Medical Director, Chief Operating Officer	Q2 In progress
WHO Checklist Compliance (Follow Up)	026		To review action taken to improve arrangements following the 2019/20 internal audit review.	Executive Medical Director cc Director of Nursing & Patient Experience	Q3
Safeguarding	027		To review Health Board arrangements to ensure the safeguarding of patients within its care.	Director of Nursing & Patient Experience	Q2 In progress
Mortality Reviews	028		To review arrangements in place to learn lessons following patient deaths and provide assurance to the Board.	Executive Medical Director	Q4

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Clinical governance quality & safety domain sub-total	8→6 Audits				
Information Governance	and Secu	rity			
IM&T Control & Risk Assessment	029		To review and assess the control environment for the management of IM&T within the organisation	Chief Digital Officer cc Chief Operating Officer, Director of Corporate Governance	Q3 In progress
IT Application Systems	030		To review the implementation & management of controls in respect of a key IT system.	Chief Digital Officer cc Chief Operating Officer	Q3
Information Governance and Security domain sub-total	2 Audits				

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)				
Operational service and functional management									
Singleton & Neath Port Talbot Unit Governance	031	63, 65, 66, 67	To review the framework of governance and risk management implemented within the Unit.	Chief Operating Officer cc Director of Corporate Governance	Q3 (Late Q3) → Defer to 2021/22				
Primary Care Unit Governance (Follow Up)	032		To review action taken to improve arrangements following the 2019/20 internal audit review.	Chief Operating Officer	Q4 → Defer to 2021/22				
Maternity Services	033	63, 65	To review the arrangements in place to ensure quality & safety within Maternity Services and action taken following the management self-assessment and submission to Welsh Government.	Chief Operating Officer cc Director of Nursing & Patient Experience, Executive Medical Director	Q2 → Defer for consideration in 2021/22 planning				
GP OOH Services (Follow Up)	035		To review progress in monitoring & addressing issues identified during the 2019/20 internal audit review.	Chief Operating Officer	Q3/4 → Defer to 2021/22				
Integrated Care Fund Expenditure ^{c/fwd}	043		The overall objective of this audit is to review the decision and authorisation processes for ICF payments and the partnership governance arrangements supporting them.	Director of Strategy / Director of Finance	Q2 → Q3				

Planned output	Audit Ref 5→1	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Operational service and functional management domain sub-total	Audits				
Workforce management					
Agency Staff Management	038	42	To review systems in place for the engagement and control of agency staff within nursing, therapies and health sciences	Director of Workforce & Organisational Development cc Chief Operating Officer, Director of Nursing & Patient Experience, Executive Medical Director	Q3 → Q4
Medical Recruitment	039	3	To review the arrangements in place to recruit to medical posts.	Director of Workforce & Organisational Development cc Executive Medical Director	Q4 TBC → Defer to 2021/22
Nurse Staffing levels Act	040	51	To review arrangements in place to ensure that the organisation complies with the requirements of the Nurse Staffing Levels (Wales) Act 2016.	Director of Nursing & Patient Experience	Q3 In Progress

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Locum On Duty	041	42	To review progress with implementation of the Locum on Duty electronic system, and assess the extent to which the system of control as implemented via the electronic system addresses control weaknesses raised in the audit review of medical agency locums.	Executive Medical Director Cc Director of Workforce & Organisational Development, Chief Operating Officer	Q3 → Q3/Q4
Workforce management domain sub-total	4→3 Audits				
Capital & Estates	1				
External Reporting					
Environmental Sustainability Reporting	042		To review and comment on compliance with guidance and information reported.	Director of Strategy Cc Director of Corporate Governance	Q2 FINAL
Follow Up (Capital)	1				
Follow up (Capital)	S01		To deliver reasonable assurance to the Audit Committee that appropriate management action has been taken to address agreed audit recommendations arising from the capital reports previously issued.	Director of Strategy	Q4

_	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
Major Strategic Investment	Progra	mmes			
	S02		NHS Wales Infrastructure Investment Guidance (updated guidance issued by Welsh Government in October 2018) requires an Integrated Assurance and Approval Plan (IAAP), which sets out assurance and approval points for each stage of the Business Case process. Accordingly, the organisation is required to outline the various formalised assurance mechanisms proposed (e.g. internal audit, Gateway reviews, functional reviews etc.) and the timing of each. The Integrated Audit Plans proposed include a combination of programme-level, functional and consultancy assurance that, when combined, provide a balanced programme for the client to achieve the desired level of assurance required by Welsh Government. Accordingly we will seek to develop IAP's for the projects	Director of Strategy	Q1-4 (Not a review – proactive support for inclusion within business cases)

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)
			the development of the respective OBC/FBCs).		
Major Strategic Investment Programmes: ARCH Programme	S10	13	Dovetailing with internal audit, assessing the robustness of arrangements to deliver the ARCH Programme requirements, the same may include an assessment of programme management and delivery arrangements or emphasis on individual project elements. Additionally the benefits of an integrated assurance plan will be assessed.	Director of Strategy	Q2 In progress
Singleton Hospital Cladding Façade	S03		To assess the delivery of this £10m capital project, currently progressing through the appointment of its supply chain partner, through to design completion, approval and commencement on site.	Director of Strategy	Q3 → Defer to 2021/22
Environmental / Infrastructure Modernisation Programme	S04	13	An assessment of the delivery of the latest phase of the Infrastructure Modernisation Programme.	Director of Strategy	Q3 → Q3/Q4

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)			
Informatics Modernisation Programme								
Informatics SOP	S05		Building on previous audit reviews of the UHB IM&T strategy, it is proposed that this will be further tested via appropriate sampling. Including e.g. the updated maintenance of the UHB strategy; risk management arrangements and the testing of the delivery of IM&T infrastructure projects allocated within the discretionary capital programme.	Chief Operating Officer	Q3 → Remove			
Capital Systems								
Capital Systems	S06		To confirm that there are effective systems operating to manage delivery of the Health Board's discretionary capital programme in accordance with the Welsh Government Capital Resource Limit.	Director of Strategy	Q2 In progress			

Planned output	Audit Ref	HBRR Ref	Outline Scope	Executive Lead	Outline timing (fieldwork commencement)			
Estates Assurance								
Follow up (Estates Assurance)	S07		To deliver reasonable assurance to the Audit Committee that appropriate management action has been taken to address agreed audit recommendations arising from the estates assurance reports previously issued.		Q4			
Water Safety (Follow Up and Additional site Testing)	S08		Recognising the limited assurance Water Safety Audit delivered during 2019/20, it is proposed that a follow up review be undertaken including additional testing at UHB premises not incorporated within the original audit.	Officer / Director of Nursing & Patient	Q2-Q3			
Fire Safety	S09		To review arrangements in place to provide assurance to the Board that fire risks are managed effectively	Chief Operating Officer / Director of Nursing & Patient Experience	Q3			
Capital & Estates domain sub-total	11→8 Audits							